Formulations of ammonium chloride to support human natural defense against viruses
OwnerNikolaos Tsirikos-Karapanos, Nikolaos Drakoulisinventors
Life of this patent
Estimating the term…
Abstract
Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.
Claims20
A formulation for militating against a clinical manifestation of infection by a virus in a subject, the formulation comprising:
- a lysosomotropic agent including ammonium chloride in an amount from about 10 mg to about 2,000 mg;
- wherein the formulation is configured in a unit dosage form and includes an enteric coating configured for oral administration that provides a sustained release of the ammonium chloride.
A method of militating against a clinical manifestation of infection by a virus in a subject, the method comprising:
- administering a formulation to the subject, the formulation including a lysosomotropic agent having ammonium chloride in an amount from about 10 mg to about 2,000 mg, the formulation configured in a unit dosage form, and the formulation having an enteric coating configured for oral administration that provides a sustained release of the ammonium chloride;
- monitoring the subject for at least one of alkalosis and acidosis, wherein the monitoring includes measuring a blood pH of the subject;
- selectively adjusting the administering of the formulation to the subject based on the monitoring so that the subject is not exhibiting alkalosis and is not exhibiting acidosis, wherein the selectively adjusting includes adjusting the administering of the formulation to the subject until the blood pH of the subject is between about 7.35 and about 7.45;
- and
- continuing the administering of the formulation over a period of at least 24 hours to reduce intracellular viral load at 24 hours post-infection.
Dependencies are inferred from the claim text.